ElectroWire Medical has received U.S. Food and Drug Administration (FDA) clearance for its LightningWire™ Transseptal Puncture System, marking an important regulatory milestone for the company's cardiovascular device portfolio.
The system is designed to create an opening in the atrial septum, enabling physicians to introduce cardiovascular catheters into the left side of the heart during minimally invasive procedures.
The LightningWire system combines an electrosurgical guidewire with a dedicated activation cable that works with existing electrosurgical generators and commonly used transseptal introducers.
Its insulated guidewire is designed to deliver reliable electrosurgical performance while providing the mechanical strength required to support the delivery of treatment devices.
The activation cable also enables clinicians to control radiofrequency energy directly from the sterile field.
The device is intended for use across a range of structural heart and electrophysiology procedures, including catheter ablation for atrial fibrillation, left atrial appendage closure, and transcatheter mitral valve repair and replacement.
ElectroWire Medical believes the technology will improve procedural efficiency while remaining compatible with established clinical workflows.
Following FDA clearance, the company plans a limited commercial launch of the LightningWire system.
Based in Lexington, South Carolina, ElectroWire Medical is also advancing its commercial strategy and fundraising efforts to support wider market adoption and future business growth.
